Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer.

Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J.

J Thorac Oncol. 2011 Apr;6(4):790-5. doi: 10.1097/JTO.0b013e3182103b51.

PMID:
21325974
[PubMed - indexed for MEDLINE]
2.

Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.

Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, Sugino Y, Yamamoto M, Ogasawara T, Kondo M, Imaizumi K, Hasegawa Y, Suzuki R, Shimokata K; Central Japan Lung Study Group.

Anticancer Drugs. 2011 Sep;22(8):811-6. doi: 10.1097/CAD.0b013e3283440231.

PMID:
21317767
[PubMed - indexed for MEDLINE]
3.

An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.

Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D.

J Thorac Oncol. 2011 Aug;6(8):1400-6. doi: 10.1097/JTO.0b013e31820d7805.

PMID:
21673602
[PubMed - indexed for MEDLINE]
4.

S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.

Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H.

Clin Cancer Res. 2004 Dec 1;10(23):7860-4.

PMID:
15585618
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).

Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group.

J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c.

PMID:
19884859
[PubMed - indexed for MEDLINE]
6.

Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.

Takiguchi Y, Seto T, Ichinose Y, Nogami N, Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, Nishikawa M, Watanabe K.

J Thorac Oncol. 2011 Jan;6(1):156-60. doi: 10.1097/JTO.0b013e3181f7c76a.

PMID:
21107293
[PubMed - indexed for MEDLINE]
7.

A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.

Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, Yoshioka H, Hayashi H, Kawai H, Aoe K, Maeda T, Ueoka H, Tanimoto M.

J Thorac Oncol. 2010 Sep;5(9):1430-4. doi: 10.1097/JTO.0b013e3181e3248e.

PMID:
20651615
[PubMed - indexed for MEDLINE]
8.

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.

Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H; S-1 Cooperative Study Group (Lung Cancer Working Group).

Br J Cancer. 2001 Sep 28;85(7):939-43.

PMID:
11592762
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.

Totani Y, Saito Y, Hayashi M, Tada T, Kohashi Y, Mieno Y, Kato A, Imizu H, Yoneda Y, Hoshino T, Uchiyama Y, Takeuchi Y, Okazawa M, Sakakibara H.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1181-5. doi: 10.1007/s00280-009-0981-1. Epub 2009 Apr 18.

PMID:
19377885
[PubMed - indexed for MEDLINE]
10.

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T.

Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.010. Epub 2011 Sep 3.

PMID:
21890422
[PubMed - indexed for MEDLINE]
11.

A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.

Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y, Fukuoka M.

J Thorac Oncol. 2010 May;5(5):702-6. doi: 10.1097/JTO.0b013e3181ce3e22.

PMID:
20150827
[PubMed - indexed for MEDLINE]
12.

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara RH, Zang EA, Cole PE, Shuster D, Das A.

Clin Lung Cancer. 2012 Jan;13(1):31-8. doi: 10.1016/j.cllc.2011.06.010. Epub 2011 Sep 8.

PMID:
21862415
[PubMed - indexed for MEDLINE]
13.

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).

Choy H, Devore RF 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):931-7.

PMID:
10863062
[PubMed - indexed for MEDLINE]
14.

Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.

Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M.

J Thorac Oncol. 2009 Dec;4(12):1530-6. doi: 10.1097/JTO.0b013e3181b9e608.

PMID:
19755925
[PubMed - indexed for MEDLINE]
15.

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM.

Clin Cancer Res. 2010 Apr 15;16(8):2450-7. doi: 10.1158/1078-0432.CCR-09-1920. Epub 2010 Mar 23.

PMID:
20332327
[PubMed - indexed for MEDLINE]
Free Article
16.

[S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer].

Hashizume T, Nakada Y.

Gan To Kagaku Ryoho. 2009 Jun;36(6):963-7. Japanese.

PMID:
19542716
[PubMed - indexed for MEDLINE]
17.

[S-1 activity in non-small cell lung cancer in clinical practice].

Inagaki M, Onuki T, Iguchi K, Ogata T, Hayashi Y, Saito K, Wakai Y, Takabe K, Shinohara Y, Suzuki K, Ohtani T, Horikoshi K.

Gan To Kagaku Ryoho. 2009 May;36(5):763-7. Japanese.

PMID:
19461174
[PubMed - indexed for MEDLINE]
18.

Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).

Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, Wada H.

Eur J Cardiothorac Surg. 1998 Sep;14(3):256-62; discussion 263-4.

PMID:
9761434
[PubMed - indexed for MEDLINE]
19.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.

Wada M, Yamamoto M, Ryuge S, Nagashima Y, Hayashi N, Maki S, Otani S, Katono K, Takakura A, Yanaihara T, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Masuda N.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1005-11. doi: 10.1007/s00280-011-1795-5. Epub 2011 Dec 8.

PMID:
22160350
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk